Yi-Ching Wang, Ph.D.
Department of Pharmacology, College of Medicine
National Cheng Kung University
No. 1 University Road, Tainan 701, Taiwan
Phone No: 06-2353535 ext.5502
Fax No: 06-2749296
E-mail: ycw5798@mail.ncku.edu.tw
Web: https://ycw-lab.webnode.tw/yi-ching-wang/

Education

1983-1987	B.S., Chinese Culture University, Taiwan
1988-1993	Ph.D., Michigan State University, USA

Research and Professional Positions Held in Chronological Sequence

1993-1995	Post-doctoral fellow, Institute of Biomedical Sciences, Academia Sinica, Taiwan
1995-1999	Associate Professor, Institute of Toxicology, Chung Shan Medical University, Taiwan
1999-2006	Professor, Department of Life Science, National Taiwan Normal University, Taiwan
2006-2015	Distinguished Professor, Department of Pharmacology & Institute of Basic Medical Science, National Cheng Kung University, Tainan, Taiwan
2015-present	Chair Professor, Department of Pharmacology & Institute of Basic Medical Science, National Cheng Kung University, Tainan, Taiwan
2023-present	Director, Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Research Interests

Dr. Yi-Ching Wang has a long-standing research interest in the molecular mechanisms underlying tumorigenesis, with a primary focus on lung cancer. More recently, her team has expanded their studies to include esophageal carcinoma, pancreatic cancer, and colorectal cancer-among the leading causes of cancer-related deaths worldwide. Her research investigates the etiological roles of tumor suppressor gene and oncogene alterations in cancer signaling pathways, leveraging cancer genomics and epigenomics to identify novel genes critical to tumor development. In recent years, Dr. Wang has directed increasing attention to the study of post-translational modifications of immune inhibitory receptors on T cells, as well as the functional role of Rab37, a small GTPase, in regulating exocytosis and its dysregulation in tumorigenesis and the tumor microenvironment. Her team is actively engaged in the development of novel anti-cancer therapeutics and immunomodulatory antibodies. As a Principal Investigator for the past three decades, Dr. Wang has published 143 SCI-indexed papers (i10-index: 125) in high-impact journals including *Journal of Clinical Investigation*, *Nature Communications*, *Nucleic Acids Research*, *Journal of Thoracic Oncology*, *Cell Death & Differentiation*, *Cancer Research*, *Science Advances*, and *Theranostics*. She has an H-index of 50. In addition, her group has presented 398 conference papers, authored 4 book chapters, and secured 5 Taiwan patents, 3 US patents, and 1 PCT patent, with one technology transferred.

Major Honors and Awards

2024	NSTC Appointed Outstanding Research Award
2023	Tien Te Lee Biomedical Foundation for Excellent Biomedical Award
2022	The Ministry of Education's 66th Annual Academic Award
2021	The Foundation for the Advancement of Outstanding Scholarship Award
2018	K. T. Li Honorary Scholar Award
2017	Dr. Wang Min-Ning Memory Foundation for Excellent Basic Medical Research award
2004,2010,2014	Outstanding Research Award of NSC / MOST
2013	Dr. Tung Ta-Cheng Memorial Award for Basic Cancer Research, Chinese Oncology Society
2011	Outstanding research paper award of National Cheng Kung University
2008-2024	Outstanding research paper award of Cheng Hsin Foundation, Taiwan
2008	Research Award of the Pharmacology Society, Taiwan
2007	Distinguished alumnus of Chinese Culture University, Taiwan

Selected Publications in Five Years

1. Hsieh HC, Young MJ, Chen KY, Su WC, Lin CC, Yen YT, Hung JJ*, **Yi-Ching Wang***. **2025**. Inhibition of USP24 augments T-cell anti-tumor immunity by destabilizing PD-1. ***Science Advances*** 11(16):eadt4258.
2. WT Kuo, IY Kuo, HC Hsieh, ST Wu, WC Su, **Yi-Ching Wang***. **2024**. Rab37 mediates trafficking and membrane presentation of PD-1 to sustain T cell exhaustion in lung cancer**. *J Biomed Sci.*** 7;31(1):20.
3. Hsieh CH, Ho PS, Wang WL, Shih FH, Hong CT, Wang PW, Shieh DB, Chang WL, **Yi-Ching Wang***. **2024**. Decreased plasma gelsolin fosters a fibrotic tumor microenvironment and promotes chemoradiotherapy resistance in esophageal squamous cell carcinoma. ***J Biomed Sci.*** 31(1):90.
4. PS Yang, MH Yu, YC Hou, CP Chang, SC Lin, IY Kuo, PC Su, HC Cheng, WC Su, YS Shan*, **Yi-Ching Wang***. **2022**. Targeting protumor factor chitinase-3-like-1 secreted by Rab37 vesicles for cancer immunotherapy. ***Theranostics,*** 12(1):340-361. **(cover article)**
5. CH Hsieh, WH Kuan, WL Chang, IY Kuo, H Liu, DB Shieh, H Liu, B Tan, **Yi-Ching Wang***. **2022**. Dysregulation of SOX17/NRF2 axis confers chemoradiotherapy resistance and emerges as a novel therapeutic target in esophageal squamous cell carcinoma. ***J Biomed Sci.*** 29(1):90.
6. IY Kuo, YE Yang, PS Yang, YJ Tsai, HT Tzeng, HC Cheng, WT Kuo, WC Su, CP Chang*, **Yi-Ching Wang***. **2021.** Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment. ***Theranostics*** 11(14):7029-7044. **(cover article)**
7. CH Hsieh, HC Hsieh, FH Fu, PW Wang, LX Yang, DB Shieh*, **Yi-Ching Wang*. 2021**. An innovative NRF2 nano-modulator induces lung cancer ferroptosis and elicits an immunostimulatory tumor microenvironment. ***Theranostics,*** 11(14):7072-7091. **(cover article)**